Salix Pharmaceuticals, Inc.
Salix Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and focuses primarily on gastrointestinal (GI) disorders. Founded in 2001, Salix has established itself as a leader in developing innovative therapies that address unmet medical needs in the GI space. The company’s core products, including treatments for conditions such as irritable bowel syndrome and inflammatory bowel disease, are distinguished by their efficacy and patient-centric approach. With a strong market position, Salix has achieved significant milestones, including the successful launch of several key medications that have transformed patient care. The company’s commitment to research and development, alongside its strategic partnerships, has solidified its reputation as a trusted provider of specialised GI therapies, making it a vital contributor to the healthcare landscape.
DitchCarbon Score
How does Salix Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Salix Pharmaceuticals, Inc.'s score of 30 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Salix Pharmaceuticals, Inc.'s reported carbon emissions
Salix Pharmaceuticals, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or the scope of their emissions (Scope 1, 2, or 3). However, the absence of documented reduction initiatives or climate pledges suggests that the company may still be in the early stages of formalising its climate commitments. As the pharmaceutical industry increasingly prioritises sustainability, it is essential for companies like Salix to establish clear targets and strategies to address climate change and reduce their environmental impact.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Salix Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
